Synthesis of Substituted Aryl Incorporated Oxazolo[4,5-b]Pyridine-Triazole Derivatives: Anticancer Evaluation and Molecular Docking Studies

References

• A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians 61, no. 2 (2011): 69–90.
   PubMed Web of Science ®Google Scholar
• B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang, and B. Baradaran, “The Different Mechanisms of Cancer Drug Resistance: A Brief Review,” Advanced Pharmaceutical Bulletin 7, no. 3 (2017): 339–48.
   PubMed Web of Science ®Google Scholar
• P. E. Clayton, I. Banerjee, P. G. Murray, and A. G. Renehan, “Growth Hormone, the Insulin-like Growth Factor Axis, Insulin and Cancer Risk,” Nature Reviews. Endocrinology 7, no. 1 (2011): 11–24.
   PubMed Web of Science ®Google Scholar
• M. R. Clemens, “Free Radicals in Chemical Carcinogenesis,” Klinische Wochenschrift 69, no. 21–23 (1991): 1123–34.
   PubMedGoogle Scholar
• A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-Related Inflammation,” Nature 454, no. 7203 (2008): 436–44.
   PubMed Web of Science ®Google Scholar
• M. K. Meffert, J. M. Chang, B. J. Wiltgen, M. S. Fanselow, and D. Baltimore, “NF-Kappa B Functions in Synaptic Signaling and Behavior,” Nature Neuroscience 6, no. 10 (2003): 1072–8.
   PubMed Web of Science ®Google Scholar
• S. K. Park, L. Y. Cho, J. J. Yang, B. Park, S. H. Chang, K. S. Lee, H. Kim, K. Y. Yoo, and C. T. Lee, “Lung Cancer Risk and Cigarette Smoking, Lung Tuberculosis according to Histologic Type and Gender in a Population Based Case-Control Study,” Lung Cancer 68, no. 1 (2010): 20–6.
   PubMed Web of Science ®Google Scholar
• C. Porta, E. Riboldi, and A. Sica, “Mechanisms Linking Pathogens-Associated Inflammation and Cancer,” Cancer Letters 305, no. 2 (2011): 250–62.
   PubMed Web of Science ®Google Scholar
• F. A. Khan, S. S. Akhtar, and M. K. Sheikh, “Cancer Treatment - Objectives and Quality of Life Issues,” Malaysian Journal of Medical Sciences 12, no. 1 (2005): 3–5.
   PubMedGoogle Scholar
• M. Agarwal, V. Singh, S. C. Sharma, P. Sharma, Md, Y. Ansari, S. S. Jadav, S. Yasmin, R. Sreenivasulu, Md Z. Hassan, P. Saini, et al. “Design and Synthesis of New 2,5-Disubstituted-1,3,4-Oxadiazole Analogues as Anticancer Agents,” Medicinal Chemistry Research 25, no. 10 (2016): 2289–303.
   Web of Science ®Google Scholar
• M. J. Ahsan, K. Choudhary, S. S. Jadav, S. Yasmin, M. Y. Ansari, and R. Sreenivasulu, “Synthesis, Antiproliferative Activity, and Molecular Docking Studies of Curcumin Analogues Bearing Pyrazole Ring,” Medicinal Chemistry Research 24, no. 12 (2015): 4166–80.
   Web of Science ®Google Scholar
• R. Durgesh, R. Sreenivasulu, and R. R. Raju, “Synthesis and anti-Tumor Evaluation of Indole-Substituted Indole Fused Keto Hydrazide-Hydrazones,” Journal of Pharmacy Research 12, no. 1 (2018): 42–6.
   Google Scholar
• Durgesh Rudavath, Reddymasu Sreenivasulu, Srinivasa Rao Pinapati, and Rudraraju Ramesh Raju, “Synthesis and anti-Tumor Evaluation of Novel 5-Bromo Indole-Aryl Ketohydrazide-Hydrazone Analogues,” Asian Journal of Chemistry 30, no. 6 (2018): 1201–4.
   Google Scholar
• R. Durgesh, R. Sreenivasulu, P. Srinivasarao, and R. R. Raju, “Synthesis and Anticancer Evaluation of Indazole-Aryl Hydrazide-Hydrazone Derivatives,” Journal of Indian Chemical Society 95, no. 6 (2018): 433–8.
   Google Scholar
• I. Hatti, R. Sreenivasulu, S. S. Jadav, M. J. Ahsan, and R. R. Raju, “Synthesis and Biological Evaluation of 1,3,4-Oxadiazole-Linked Bisindole Derivatives as Anticancer Agents,” Monatshefte Für Chemie - Chemical Monthly 146, no. 10 (2015): 1699–705.
   Google Scholar
• I. Hatti, R. Sreenivasulu, S. S. Jadav, V. Jayaprakash, C. G. Kumar, and R. R. Raju, “Synthesis, Cytotoxic Activity and Docking Studies of New 4-Aza-Podophyllotoxin Derivatives,” Medicinal Chemistry Research 24, no. 8 (2015): 3305–13.
   Web of Science ®Google Scholar
• S. Madhavi, R. Sreenivasulu, Md Y. Ansari, M. J. Ahsan, and R. R. Raju, “Synthesis, Biological Evaluation and Molecular Docking Studies of Pyridine Incorporated Chalcone Derivatives as Anticancer Agents,” Letters in Organic Chemistry 13, no. 9 (2016): 682–92.
   Web of Science ®Google Scholar
• Sapavat Madhavi, Reddymasu Sreenivasulu, Jyothsna Pragathi Yazala, and Rudraraju Ramesh Raju, “Synthesis of Chalcone Incorporated Quinazoline Derivatives as Anticancer Agents,” Saudi Pharmaceutical Journal: SPJ: The Official Publication of the Saudi Pharmaceutical Society 25, no. 2 (2017): 275–9.
   PubMed Web of Science ®Google Scholar
• S. Madhavi, R. Sreenivasulu, and R. R. Raju, “Synthesis and Biological Evaluation of Oxadiazole Incorporated Ellipticine Derivatives as Anticancer Agents,” Monatshefte Für Chemie - Chemical Monthly 148, no. 5 (2017): 933–8.
   Google Scholar
• I. S. Murthy, R. Sreenivasulu, G. Alluraiah, and R. R. Raju, “Design, Synthesis and Anticancer Activity of 1,2,3-Triazole Linked 1,2-Isoxazole - Imidazo[4,5-b]Pyridine Derivatives,” Russian Journal of General Chemistry 89, no. 8 (2019): 1718–23.
   Web of Science ®Google Scholar
• T. Yakantham, R. Sreenivasulu, and R. R. Raju, “Design, Synthesis and Anticancer Evaluation of 2-(3-(4-((5-Aryl-1,2,4-Oxadiazol-3-yl)Methoxy)Phenyl)Isoxazol-5-yl)-N-(3,4,5-Trimethyl Phenyl) Thiazol-4-Amine Derivatives,” Russian Journal of General Chemistry 89, no. 7 (2019): 1485–90.
   Web of Science ®Google Scholar
• Z. Spandana, R. Sreenivasulu, and M. V. B. Rao, “Design, Synthesis and Anticancer Evaluation of Carbazole Fused Aminopyrimidine Derivatives,” Letters in Organic Chemistry 16, no. 8 (2019): 662–7.
   Web of Science ®Google Scholar
• Z. Spandana, R. Sreenivasulu, T. M. Rekha, and M. V. B. Rao, “Novel 1,3,4-Oxadiazole Fused Thiadiazole Derivatives: Synthesis and Study of Anticancer Activities,” Letters in Drug Design & Discovery 16, no. 6 (2019): 656–62.
   Web of Science ®Google Scholar
• R. Sreenivasulu, R. Durgesh, S. S. Jadav, P. Sujitha, C. G. Kumar, and R. R. Raju, “Synthesis, Anticancer Evaluation and Molecular Docking Studies of Bis(Indolyl) Triazinones, Nortopsentin Analogues,” Chemical Papers 72, no. 6 (2018): 1369–78.
   Web of Science ®Google Scholar
• R. Sreenivasulu, K. T. Reddy, S. S. Jadav, P. Sujitha, C. G. Kumar, and R. R. Raju, “Synthesis, Antiproliferative and Apoptosis Induction Potential Activities of Novel bis(indolyl)hydrazide-hydrazone derivatives,” Bioorganic & Medicinal Chemistry 27, no. 6 (2019): 1043–55.
   PubMed Web of Science ®Google Scholar
• R. Sreenivasulu, P. Sujitha, S. S. Jadav, M. J. Ahsan, C. G. Kumar, and R. R. Raju, “Synthesis, Antitumor Evaluation and Molecular Docking Studies of Indole – Indazolyl Hydrazide – Hydrazone Derivatives,” Monatshefte Für Chemie – Chemical Monthly 148, no. 2 (2017): 305–14.
   Google Scholar
• M. Subramanyam, R. Sreenivasulu, G. Rambabu, M. V. B. Rao, and K. P. Rao, “Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs,” Letters in Drug Design & Discovery 15, no. 12 (2018): 1299–307.
   Web of Science ®Google Scholar
• V. R. Suma, R. Sreenivasulu, M. Subramanyam, and K. R. M. Rao, “Design, Synthesis and Anticancer Evaluation of Amide Derivatives of Structurally Modified Combretastatin A4 as Anticancer Agents,” Russian Journal of General Chemistry 89, no. 3 (2019): 499–504.
   Web of Science ®Google Scholar
• Y. J. Pragathi, R. Sreenivasulu, D. Veronica, S. Madhavi, and R. R. Raju, “Design, Synthesis and Biological Evaluation of Novel 2-(4-Arylsubstituted-1H-1,2,3-Triazol-1-yl)-N-(4-(2-(Thiazol-2-yl)Benzo[d]Thiazol-6-yl)Phenyl) Acetamide Derivatives as Potent Anticancer Agents,” Russian Journal of General Chemistry 89, no. 5 (2019): 1009–14.
   Web of Science ®Google Scholar
• K. T. Reddy, R. Sreenivasulu, and R. R. Raju, “Synthesis and Biological Evaluation of 1,2,4-Oxadiazole Linked Imidazopyrazine Derivatives as Anticancer Agents,” Journal of Indian Chemical Society 96, no. 8 (2019): 1085–90.
   Web of Science ®Google Scholar
• N. B. Reddy, V. R. Burra, L. K. Ravindranath, V. N. Kumar, R. Sreenivasulu, and P. Sadanandam, “Synthesis and Biological Evaluation of Benzimidazole Fused Ellipticine Derivatives as Anticancer Agents,” Monatshefte Für Chemie – Chemical Monthly 147, no. 3 (2016): 599–604.
   Google Scholar
• S. Shahinshavali, R. Sreenivasulu, V. R. Guttikonda, D. Kolli, and M. V. B. Rao, “Synthesis and Biological Evaluation of Amide Derivatives of 1,2-Isoxazole Fused 1,2,4-Thiadiazole as Anticancer Agents,” Russian Journal of General Chemistry 89, no. 2 (2019): 324–9.
   Web of Science ®Google Scholar
• N. B. Reddy, V. R. Burra, L. K. Ravindranath, R. Sreenivasulu, and V. N. Kumar, “Synthesis and Biological Evaluation of Benzoxazole Fused Combretastatin Derivatives as Anticancer Agents,” Monatshefte Für Chemie – Chemical Monthly 147, no. 3 (2016): 593–8.
   Google Scholar
• E. Oksuzoglu, B. Tekiner-Gulbas, S. Alper, O. Temiz-Arpaci, T. Ertan, I. Yildiz, N. Diril, E. Sener-Aki, and I. Yalcin, “Some Benzoxazoles and Benzimidazoles as DNA Topoisomerase I and II Inhibitors,” Journal of Enzyme Inhibition and Medicinal Chemistry 23, no. 1 (2008): 37–42.
   PubMed Web of Science ®Google Scholar
• A. Darque, A. Dumetre, S. Hutter, G. Casano, M. Robin, C. Pannecouque, and N. Azas, “Synthesis and Biological Evaluation of New Heterocyclic Quinolinones as Anti-Parasite and Anti-HIV Drug Candidates,” Bioorganic & Medicinal Chemistry Letters 19, no. 20 (2009): 5962–4.
   PubMed Web of Science ®Google Scholar
• C. J. O’Donnell, B. N. Rogers, B. S. Bronk, D. K. Bryce, J. W. Coe, K. K. Cook, A. J. Duplantier, E. Evrard, M. Hajos, W. E. Hoffmann, et al. “Discovery of 4-(5-Methyloxazolo[4,5-b]Pyridin-2-yl)-1,4-Diazabicyclo [3.2.2]Nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models,” Journal of Medicinal Chemistry 53, no. 3 (2010): 1222–37.
   PubMed Web of Science ®Google Scholar
• Jarmila Vinsova, Katerina Cermakova, Alexandra Tomeckova, Martina Ceckova, Josef Jampilek, Pavel Cermak, Jiri Kunes, Martin Dolezal, and Frantisek Staud, “Synthesis and Antimicrobial Evaluation of New 2-Substituted 5,7-di-Tert-Butylbenzoxazoles,” Bioorganic & Medicinal Chemistry 14, no. 17 (2006): 5850–65.
   PubMed Web of Science ®Google Scholar
• R. N. Brown, R. Cameron, D. K. Chalmers, S. Hamilton, A. Luttick, G. Y. Krippner, D. B. McConnell, R. Nearn, P. C. Stanislawski, S. P. Tucker, et al. “2-Ethoxybenzoxazole as a Bioisosteric Replacement of an Ethyl Benzoate Group in a Human Rhinovirus (HRV) Capsid Binder,” Bioorganic & Medicinal Chemistry Letters 15, no. 8 (2005): 2051–5.
   PubMed Web of Science ®Google Scholar
• S. M. Coutts, A. Khandwala, and I. Weinry, “REV 2871 (CHBZ): A Potent Antiallergic Agent with a Novel Mechanism of Action. II. Studies on the Mechanism of Action,” Biochemical Pharmacology 36, no. 5 (1987): 673–82.
   PubMed Web of Science ®Google Scholar
• M. Ikeguchi, M. Sawaki, H. Nakayama, H. Kikugawa, and H. Yoshii, “Comparative Analysis of Neonicotinoid Binding to Insect Membranes: I. A Structure–Activity Study of the Mode of [3H]Imidacloprid Displacement in Myzus persicae and Aphis craccivora,” Pest Management Science 60, no. 10 (2004): 945–58.
   PubMed Web of Science ®Google Scholar
• B. T. Gulbas, O. Temiz-Arpaci, I. Yildiz, and N. Altanlar, “Synthesis and in Vitro Antimicrobial Activity of New 2-[p-Substituted-Benzyl]-5-[Substituted-Carbonylamino]Benzoxazoles,” European Journal of Medicinal Chemistry 42, no. 10 (2007): 1293–9.
   PubMed Web of Science ®Google Scholar
• E. Akıener, K. Kamuran, I. Oren, O. Temiz Arpac, S. Yalcın, and N. Altanlar, “Synthesis and Microbiological Activity of Some N-(o-Hydroxyphenyl)Benzamides and Phenylacetam Ides as the Possible Metabolites of Antimicrobial Active Benzoxazoles: Part II,” Il Farmaco 55, no. 6–7 (2000): 469–76.
   PubMedGoogle Scholar
• E. H. Sessions, Y. Yin, T. D. Bannister, A. Weiser, E. Griffin, J. Pocas, M. D. Cameron, C. Ruiz, L. Lin, S. C. Schurer, et al. “Benzimidazole- and Benzoxazole-Based Inhibitors of Rho Kinase,” Bioorganic & Medicinal Chemistry Letters 18, no. 24 (2008): 6390–3.
   PubMed Web of Science ®Google Scholar
• D. Clark, P. Eastwood, N. Harris, C. McCarthy, A. Morley, and S. Pickett, (2000) PCT WO00/49005.
   Google Scholar
• M. L. McKee, and S. M. Kerwin, “Synthesis, Metal Ion Binding, and Biological Evalustion of New Anticancer 2-(2′-Hydroxyphenyl)Benzoxazole Analogs of UK-1,” Bioorganic & Medicinal Chemistry 16, no. 4 (2008): 1775–83.
   PubMed Web of Science ®Google Scholar
• M. A. Tantray, I. Khan, H. Hamid, M. S. Alam, S. Umar, Y. Ali, K. Sharma, and F. Hussain, “Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-Yloxy) Acetamide Derivatives as Potential anti-HIV-1 Agents,” Chemical Biology & Drug Design 87, no. 6 (2016): 918–26.
   PubMed Web of Science ®Google Scholar
• R. L. Clark, A. A. Pessolano, B. Witzel, T. Lanza, T. Y. Shen, C. G. Van Arman, and E. A. Risley, “2-(Substituted Phenyl)Oxazolo[4,5-b]Pyridines and 2-(Substituted Phenyl)Oxazolo[5,4-b]Pyridines as Nonacidic Antiinflammatory Agents,” Journal of Medicinal Chemistry 21, no. 11 (1978): 1158–62.
   PubMed Web of Science ®Google Scholar
• J. E. Bemis, C. B. Vu, R. Xie, J. J. Nunes, P. Y. Ng, J. S. Disch, J. C. Milne, D. P. Carney, A. V. Lynch, L. Jin, et al. “Discovery of Oxazolo[4,5-b]Pyridines and Related Heterocyclic Analogs as Novel SIRT1 Activators,” Bioorganic & Medicinal Chemistry Letters 19, no. 8 (2009): 2350–3.
   PubMed Web of Science ®Google Scholar
• M. Monier, D. Abdel-Latif, A. El-Mekabaty, and K. M. Elattar, “Recent Progress in the Chemistry of Heterocycles Incorporated Oxazolo[4,5-b]Pyridine and Oxazolo[5,4-b]Pyridine Skeletons,” Synthetic Communications 50, no. 1 (2020): 1–32.
   Web of Science ®Google Scholar
• M. Monier, D. Abdel‐Latif, A. El-Mekabaty, and K. M. Elattar, “Reactivity and Stereoselec Tivity of Oxazolopyridines with a Ring-Junction Nitrogen Atom,” Journal of Heterocyclic Chemistry 56, no. 12 (2019): 3172–96.
   Web of Science ®Google Scholar
• M. Monier, A. El-Mekabaty, D. Abdel‐Latif, and K. M. Elattar, “Chemistry of Bicyclic 5-6 Systems: Synthesis of Oxazolo[3,2-a]Pyridines and Their Salts with a Ringjunction,” Synthetic Communications 49, no. 20 (2019): 2591–629.
   Web of Science ®Google Scholar
• S. Katsuwa, M. Sakaiya, K. Hayashi, N. Maeda, K. Maenaka, and S. Ichikawa, JP 2018-87173 Malignant brain tumor therapeutic agent. Japanese Patent Application Laid-Open No. 2018-87173 (P2018-87173A), 2018.
   Google Scholar
• K. Bozorov, J. Zhao, and H. A. Aisa, “1,2,3-Triazole-Containing Hybrids as Leads in Medicinal Chemistry: A Recent Overview,” Bioorganic & Medicinal Chemistry 27, no. 16 (2019): 3511–31.
   PubMed Web of Science ®Google Scholar
• F. D. da Silva, M. C. B. V. de Souza, I. I. P. Frugulhetti, H. C. Castro, S. L. D. Souza, T. M. L. de Souza, D. Q. Rodrigues, A. M. T. Souza, P. A. Abreu, F. Passamani, et al. “Synthesis, HIV-RT Inhibitory Activity and SAR of 1-Benzyl-1H-1,2,3-Triazole Derivatives of Carbohydrates,” European Journal of Medicinal Chemistry 44, no. 1 (2009): 373–83.
   PubMed Web of Science ®Google Scholar
• K. Kumar, B. Pradines, M. Madamet, R. Amalvict, and V. Kumar, “1H-1,2,3-Triazole Tethered Mono- and Bis-Ferrocenylchalcone-β-Lactam Conjugates: Synthesis and Antimalarial Evaluation,” European Journal of Medicinal Chemistry 86, (2014): 113–21.
   PubMed Web of Science ®Google Scholar
• E. Bokor, T. Docsa, P. Gergely, and L. Somsak, “Synthesis of 1-(D-glucopyranosyl)-1,2,3-Triazoles and Their Evaluation as Glycogen Phosphorylase Inhibitors,” Bioorganic & Medicinal Chemistry 18, no. 3 (2010): 1171–80.
   PubMed Web of Science ®Google Scholar
• M. S. Costa, N. Boechat, E. A. Rangel, F. D. Da Silva, A. M. T. de Souza, C. R. Rodrigues, H. C. Castro, I. N. Junior, M. C. S. Lourenco, S. M. S. V. Wardell, et al. “Synthesis, Tuberculosis Inhibitory Activity, and SAR Study of N-Substituted-Phenyl-1,2,3-Triazole Derivatives,” Bioorganic & Medicinal Chemistry 14, no. 24 (2006): 8644–53.
   PubMed Web of Science ®Google Scholar
• N. A. Al-Masoudi, and Y. A. Al-Soud, “Synthesis of 1′-β-d-Glucopyranosyl-1,2,3-Triazole-4,5-Dimethanol-4,5-Bis(Isopropylcarbamate) as Potential Antineoplastic Agent,” Tetrahedron Letters 43, no. 22 (2002): 4021–2.
   Web of Science ®Google Scholar
• K. K. Kumar, S. P. Seenivasan, V. Kumar, and T. M. Das, “Synthesis of Quinolone Coupled [1,2,3]-Triazoles as a Promising Class of anti-Tuberculosis Agents,” Carbohydrate Research 346, no. 14 (2011): 2084–90.
   PubMed Web of Science ®Google Scholar
• Sungsik Cho, Sangtae Oh, Yumi Um, Ji-Hee Jung, Jungyeob Ham, Woon-Seob Shin, and Seokjoon Lee, “Synthesis of 10-Substituted Triazolyl Artemisinins Possessing Anticancer Activity via Huisgen 1,3-Dipolar Cylcoaddition,” Bioorganic & Medicinal Chemistry Letters 19, no. 2 (2009): 382–5.
   PubMed Web of Science ®Google Scholar
• K. Lal, C. P. Kaushik, and A. Kumar, “Antimicrobial Evaluation, QSAR and Docking Studies of Amide-Linked 1,4-Disubstituted 1,2,3-Bistriazoles,” Medicinal Chemistry Research 24, no. 8 (2015): 3258–71.
   Web of Science ®Google Scholar
• J. F. Lutz, Nanotechnology for Life Science Research Group. “1,3-dipolar Cycloadditions of Azides and Alkynes: A Universal Ligation Tool in Polymer and Materials Science,” Angewandte Chemie (International ed. in English) 46, no. 7 (2007): 1018–25.,
   PubMed Web of Science ®Google Scholar
• J. E. Hein, and V. V. Fokin, “Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) and beyond: new Reactivity of Copper(I) acetylides,” Chemical Society Reviews 39, no. 4 (2010): 1302–15.
   PubMed Web of Science ®Google Scholar
• R. Huisgen, and A. Padwa, 1,3-Dipolar Cycloaddition Chemistry; Ed.; Wiley: New York, 1984.
   Google Scholar
• D. Song, Y. Park, J. Yoon, W. Aman, J. M. Hah, and J. S. Ryu, “Click Approach to the Discovery of 1,2,3-Triazolylsalicylamides as Potent Aurora Kinase Inhibitors,” Bioorganic & Medicinal Chemistry 22, no. 17 (2014): 4855–66.
   PubMed Web of Science ®Google Scholar
• Srikanth Gatadi, Gauthami Pulivendala, Jitendra Gour, Satyaveni Malasala, Sushmitha Bujji, Ramulu Parupalli, Mujahid Shaikh, Chandraiah Godugu, and Srinivas Nanduri, “Synthesis and Evaluation of New 4(3H)-Quinazolinone Derivatives as Potential Anticancer Agents,” Journal of Molecular Structure 1200, (2020): 127097.
   Web of Science ®Google Scholar
• Andrijana Meščić Macan, Nataša Perin, Silvio Jakopec, Marija Mioč, Marijana Radić Stojković, Marijeta Kralj, Marijana Hranjec, and Silvana Raić-Malić, “Synthesis, Antiproliferative Activity and DNA/RNA-Binding Properties of Mono-and Bis-(1,2,3-Triazolyl)-Appended Benzimidazo[1,2-a]Quinoline Derivatives,” European Journal of Medicinal Chemistry 185, (2020): 111845.
   PubMed Web of Science ®Google Scholar
• Ute F. Röhrig, Somi Reddy Majjigapu, Aurélien Grosdidier, Sylvian Bron, Vincent Stroobant, Luc Pilotte, Didier Colau, Pierre Vogel, Benoît J. Van den Eynde, Vincent Zoete, et al. “Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition,” Journal of Medicinal Chemistry 55, no. 11 (2012): 5270–90.,
   PubMed Web of Science ®Google Scholar
• Rongshi Li, Chunwei Cheng, Maria E. Balasis, Yan Liu, Thomas P. Garner, Kenyon G. Daniel, Jerry Li, Yong Qin, Evripidis Gavathiotis, and Said M. Sebti, “Design, Synthesis and Evaluation of Marinopyrrole Derivatives as Selective Inhibitors of Mcl-1 Binding to Pro-Apoptotic Bim and Dual Mcl-1/Bcl-xL Inhibitors,” European Journal of Medicinal Chemistry 90, (2015): 315–31.
   PubMed Web of Science ®Google Scholar
• A. Corvino, R. Rosa, G. M. Incisivo, F. Fiorino, F. Frecentese, E. Magli, E. Perissutti, I. Saccone, V. Santagada, G. Cirino, et al. “Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents,” International Journal of Molecular Sciences 18, no. 11 (2017): 2332.
   PubMed Web of Science ®Google Scholar
• Y. Ahn, S. Oh, S. J. Lee, B. G. Park, Y. S. Park, W. S. Shin, H. J. Jang, J. H. Park, D. Kwon, and S. Lee, “Synthesis of Diethylamino-Curcumin Mimics with Substituted Triazolyl Groups and Their Sensitization Effect of TRAIL against Brain Cancer Cells,” Bioorganic & Medicinal Chemistry Letters 24, no. 15 (2014): 3346–50.
   PubMed Web of Science ®Google Scholar
• S. Narva, X. Xiong, X. Ma, Y. Tanaka, Y. Wu, and W. Zhang, “Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors,” ACS Omega 5, no. 33 (2020): 21181–90.
   PubMed Web of Science ®Google Scholar
• J. E. Mclean, E. A. Neidhardt, T. H. Grossman, and L. Hedstrom, “Multiple Inhibitor Analysis of the Brequinar and Leflunomide Binding Sites on Human Dihydroorotate Dehydrogenase,” Biochemistry 40, no. 7 (2001): 2194–200.  
   PubMed Web of Science ®Google Scholar
• M. E. Jones, “Pyrimidine Nucleotide Biosynthesis in Animals: genes, Enzymes, and Regulation of UMP Biosynthesis,” Annual Review of Biochemistry 49, no. 1 (1980): 253–79.
   PubMedGoogle Scholar
• V. Hines, and M. Johnston, “Analysis of the Kinetic Mechanism of the Bovine Liver Mitochondrial Dihydroorotate Dehydrogenase,” Biochemistry 28, no. 3 (1989): 1222–6.
   PubMed Web of Science ®Google Scholar
• D. B. Sykes, Y. S. Kfoury, F. E. Mercier, M. J. Wawer, J. M. Law, M. K. Haynes, T. A. Lewis, A. Schajnovitz, E. Jain, D. Lee, et al. “Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia,” Cell 167, no. 1 (2016): 171–86.  
   PubMed Web of Science ®Google Scholar
• Marcus J. G. W. Ladds, Ingeborg M. M. van Leeuwen, Catherine J. Drummond, Su Chu, Alan R. Healy, Gergana Popova, Andrés Pastor Fernández, Tanzina Mollick, Suhas Darekar, Saikiran K. Sedimbi, et al. “A DHODH Inhibitor Increases p53 Synthesis and Enhances Tumor Cell Killing by p53 Degradation Blockage,” Nature Communications 9, no. 1 (2018): 1107–20.
   PubMedGoogle Scholar
• Z. Zuo, X. Liu, X. Qian, T. Zeng, N. Sang, H. Liu, Y. Zhou, L. Tao, X. Zhou, N. Su, et al. “Bifunctional Naphtho[2,3-d][1,2,3]Triazole-4,9-Dione Compounds Exhibit Antitumor Effects in Vitro and in Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production,” Journal of Medicinal Chemistry 63, no. 14 (2020): 7633–52.  
   PubMed Web of Science ®Google Scholar
• J. F. W. McOmie, and D. E. West, “3,3′-Dihydroxybiphenyl,” Organic Syntheses 49, (1969): 50 (Collective 5, (1973): 412.
   Google Scholar
• N. Miyaura, K. Yamada, and A. Suzuki, “A New Stereospecific Cross-Coupling by the Palladium-Catalyaed Reaction of 1-Alkenylboranes with 1-Alkenyl or 1-Alkynyl Halides,” Tetrahedron Letters 20, no. 36 (1979): 3437–40.
   Web of Science ®Google Scholar
• M. A. Phillips, R. Gujjar, N. A. Malmquist, J. White, F. El-Mazouni, J. Baldwin, and P. K. Rathod, “Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity against the Malaria Parasite Plasmodium falciparum,” Journal of Medicinal Chemistry 51, no. 12 (2008): 3649–53.
   PubMed Web of Science ®Google Scholar